Clinical observations suggest that NRF2 hyperactivation in cancer cells is associated with low-level immune cell infiltrations into tumors, it remains unclear how the NRF2 activation causes the reduction of immune cell infiltration. This evidence concerns the gene NFE2L2 and cancer.